Program

Sunday, April 14, 2O19

TimeActivity
9:00 AM to 4:00 PMWorkshop Full-Day 1
A Practical Introduction to Designing Economic Evaluations
Dr. Doug Coyle, University of Ottawa; Karen Lee, CADTH; and Bernice Tsoi, CADTH
9:00 AM to 12:00 PMWorkshop AM-1
When, Why, and How to Conduct an Overview of Systematic Reviews
Dr. Michelle Pollock, Institute of Health Economics; and Dr. Lisa Hartling, University of Alberta
Workshop AM-2
A Hands-on Introduction to BUGSnet: A New Comprehensive R Package for Network Meta-Analysis
Prof. Audrey Béliveau, University of Waterloo; Devin Boyne, PhD(c), University of Calgary; Justin Slater, Lighthouse Outcomes; Dr. Paul Arora, Lighthouse Outcomes; and Dr. Darren Brenner, University of Calgary
Workshop AM-3
Applying Different Study Designs for Comparative Effectiveness Research in Health Technology Assessment
Dr. Lusine Abrahamyan, Toronto Health Economics and Technology Assessment (THETA) Collaborative; and Dr. Valeria Rac, THETA Collaborative
Workshop AM-4
How to Use Person-Level Data and Regression Analysis to Show the Value for Money of Your Health Interventions
Dr. Wanrudee Isaranuwatchai, St. Michael’s Hospital; and Dr. Kednapa Thavorn, Ottawa Hospital Research Institute
Workshop AM-5
Would You Recommend This Drug for Funding? Understanding the Role of Expert Committees
Sarah Berglas, CADTH; Adam Haynes, CADTH; Amanda Allard, CADTH; and Suzanne Laplante, CADTH
1:00 to 4:00 PMWorkshop PM-1
Rapid Reviews: From Policy Question to Research and Decision-Making
Chris Kamel, CADTH; Michelle Gibbens, CADTH; Danielle Rabb, CADTH; and Kristen Moulton, CADTH
Workshop PM-2
Evaluating a New Diagnostic Test in the Absence of a Perfect Reference Test: Applications in Health Technology Assessment
Dr. Nandini Dendukuri, McGill University Health Centre; and Ian Schiller, McGill University Health Centre
Workshop PM-3
When Off-the-Rack Doesn’t Fit: Alternative Methods for Estimating Preferences for Specific Health Conditions
Teresa Tsui, Toronto Health Economics and Assessment (THETA) Collaborative; Dr. Nicholas Mitsakakis, University of Toronto; and Dr. Murray Krahn, Toronto Health Economics and Assessment (THETA) Collaborative
Workshop PM-6
Introduction to Matching-Adjusted Indirect Comparisons: Leveraging Individual Participant Data
Kirsten Garces, Takeda Canada; Dr. Chris Cameron, Cornerstone Research Group, Inc.; Brian Hutton, Ottawa Hospital Research Institute; and Tim Disher, IWK Health Centre

Monday, April 15, 2O19

TimeActivityPresentations
7:45 to 8:45 AMBreakfast Session M1
Finding Your Dumbledore and Setting Yourself Up for Life After Hogwarts — A Rapid Mentorship Session on How to Succeed in HTA
Shannon Kelly, University of Ottawa (moderator); Dr. Jean-Éric Tarride, McMaster University; Dr. Michelle Mujoomdar, CADTH; Dr. Chris Cameron, Cornerstone Research Group Inc.; and Dr. Lisa Hartling, University of Alberta
9:00 to 9:30 AMOfficial Opening
Dr. Brian O’Rourke, President and CEO, CADTH
9:30 to 10:45 AMOpening Plenary
Disruptive Innovation: The Hope and Hype of Transformation
Every technological advance, policy change, and innovation in health care delivery brings new hope for increased patient satisfaction, better health outcomes, and improved access to care. But not every new product or new approach can deliver what it promises. In this plenary, you’ll hear about some disruptive innovations in the pipeline, the expectations patients have for system transformation, and how hype can derail evidence-driven transformation.
Dr. Irfan Dhalla, Vice President, Evidence Development and Standards, Health Quality Ontario; Colleen Flood, Professor, University of Ottawa and University Research Chair in Health Law & Policy; Carole McMahon, former patient member of the pan-Canadian Oncology Drug Review Expert Review Committee; Dr. Vinay Prasad, Associate Professor of Medicine, Oregon Health and Science University; and Frédéric Rupprecht, World Wide Vice-President, Head of Health Economics and Market Access Centre of Excellence (CoE) for Johnson & Johnson Medical Devices
11:15 AM to 12:30 PMConcurrent Session A1 — Panel Discussion
Managing the “Expense” in Expensive Drugs for Rare Diseases
Brad Alyward, MORSE Consulting (moderator); Elena Lungu, Patented Medicine Prices Review Board; Eric Lun, British Columbia Ministry of Health; Karen Voin, Canadian Life and Health Insurance Association; Dr. Megan Bettle, Health Canada; and Tanya Potashnik, Patented Medicine Prices Review Board
A1 Webinar Recording
Concurrent Session A2 — Panel Discussion
Should Suboptimal Clinical Evidence Be Used to Inform HTA Recommendations?
Alexandra Chambers, CADTH; Dr. Christopher McCabe, Institute of Health Economics; Dr. Kevin Marsh, Evidera; et Bonnie Kam, Janssen Canada (moderator)
Concurrent Session A3 — Panel Discussion
Artificial Intelligence in Health Care: Promise and Challenges
Chris Kamel, CADTH; Dr. Jeremy Petch, University of Toronto; and Dornoosh Zonoobi, MEDO.ai
Concurrent Session A4 — Panel Discussion
Understanding the Burden of Illness: Cultivating Best Practices in Patient Evidence
Dr. Chad Andrews, The Foundation Fighting Blindness; Dr. Mary Sunderland, The Foundation Fighting Blindness; Connie Côté, Health Charities Coalition of Canada; and Tamara Rader, CADTH
Concurrent Session A5 — Panel Discussion
Toward a pan-Canadian Understanding of the Economic Impacts of Cancer Care on Patients, Their Families, and Society: Implications for Decision-Making
Dr. Claire de Oliveira, University of Toronto; Dr. Beverley Essue, Canadian Partnership Against Cancer; Prof. Stuart Peacock, Canadian Centre for Applied Research in Cancer; and Dr. Murray Krahn, Toronto Health Economics and Assessment (THETA) Collaborative
Concurrent Session A6 — Panel Discussion
The Power of Real-Time Observations to Drive and Sustain Large-Scale Change
Dr. Murray Ross, Canadian Foundation for Healthcare Improvement Board of Directors’ member and Vice President, Kaiser Permanente; John Flood, Prince Edward Island Appropriate Use of Antipsychotics Collaborative; Mollie Cole, Alberta Health Services; and Dr. Serge Gingras, Centre intégré universitaire de soins et services de santé de l’Ouest de l’Île de Montréal
1:30 to 2:45 PMConcurrent Session B1 — Oral Presentations
MENTAL HEALTH AND ADDICTIONS
Accelerating Provincial Spread and Scale of Appropriate use of Antipsychotic Drugs in Long-Term Care
Tanya MacDonald, Canadian Foundation for Healthcare Improvement
Using Technology to Improve Access to Mental Health Services in Canada: A Review of the Evidence on Internet-Delivered Cognitive Behavioural Therapy
Calvin Young, CADTH
Cost Analysis of Intermittent Theta Burst Stimulation (iTBS) Versus 10Hz Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Treatment Resistant Depression
Andrew Mendlowitz, University of Toronto
Stepped-Care Treatment for Depressive Disorder May Have Economic Benefits
Dr. Charles Yan, Institute of Health Economics
Concurrent Session B2 — Oral Presentations
RURAL AND REMOTE HEALTH CARE
Making the Link: Mixed-Method Exploration of Using Telehealth to Facilitate Services Related to Autism Spectrum Disorder for Families and Health Care Providers in Rural Areas of Western Newfoundland and Labrador
Karen Lulk, Western Health
Opioid Dependency Treatment for Dispersed Populations, The Alberta Rural Opioid Dependency Program Experience and Results
Dr. Nathaniel Day, Alberta Health Services
Utilization of a Logic Model to Facilitate Systems Thinking: A Novel Model of Care for Patients with Cardiac Implantable Electronic Devices
Shannon Kelly, University of Ottawa
Patients Support a Pharmacist-Led Best Possible Medication Discharge Plan (BPMDP) Via Tele-robot in a Remote and Rural Community Hospital
Paula Newman, Northwest Telepharmacy Solutions
Concurrent Session B3 — Oral Presentations
PHARMACEUTICAL POLICY
The Relationship of Conditional Regulatory Approvals to HTA Recommendation — Outcome and Timing
Dr. Lawrence Liberti, The Centre for Innovation in Regulatory Science (CIRS)
The Impact of Pharmaceutical Innovation on the Burden of Disease in Canada, 2000-2016
Prof. Frank Lichtenberg, Columbia University
Biosimilars in Canada: Current Environment and Future Opportunity
Elena Lungu, Patented Medicine Prices Review Board
Values in the Canadian Pharmacare Debate: Implications for Pharmaceutical Policy and Systems Reform
Ana Komparic, University of Toronto
Concurrent Session B4 — Oral Presentations
PUBLIC, PATIENT, AND CAREGIVER ENGAGEMENT
(Re)defining Legitimacy? Expertise and Public and Patient Involvement in Canadian Drug Assessment
Prof. Katherine Boothe, McMaster University
Bringing Citizen-Led Research to Life: Experiences of the Ontario Drug Policy Research Network Citizens’ Panel Landscape of Prescription Stimulant Use Report
Dr. Mina Tadrous, Ontario Drug Policy Research Network
Including Patient Views in Lyme Disease Guidelines: Lessons Learned by INESSS
Dr. Mélanie Tardiff, INESSS
Comparing How Patients, Clinicians, and Managers Experience the Barriers to Meaningful Patient Engagement: Findings From a Scoping Review
Umair Majid, University of Toronto
B4 Webinar Recording
Concurrent Session B5 — Oral Presentations
DRUG COST TRENDS
Highlights of New Medicines in the Pipeline
Jared Berger, Patented Medicine Prices Review Board
Expected Impact of New Therapies for Advanced Non–small-cell lung carcinoma (NSCLC) On Patient Survival and Costs In Canada Over the Next Five Years: An Impact of Treatment Evolution in NSCLC (ITEN) Model Assessment
Dr. Parneet Cheema, University of Toronto
Uncovering the Forces Driving Costs in Canada’s Public Drug Plans
Yvonne Zhang, Patented Medicine Prices Review Board
Assessing the Potential Net Health Impact of Recommendations Made Through the CADTH Common Drug Review (CDR) Program
Cody Black, CADTH
Impact of Increasing Wait Times on the Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy in large B-cell lymphoma: A Discrete Event Simulation Model
Dr. William W.L Wong, University of Waterloo
Concurrent Session B6 — Oral Presentations
HTA METHODS
How Living Systematic Reviews Can Support Health Care Decision-Making: The Case of Cannabis for Pediatric Epilepsy
Jesse Elliott, University of Ottawa
Evaluation of Drugs for Listing Purposes: A Change of Approach at INESSS
Marie-Claude Aubin, INESSS
Bayesian Networks as an Emerging Tool for Disease Risk Estimation and Clinical Decision-Making: A Real-World Example in Coronary Artery Disease
Alind Gupta, Lighthouse Outcomes Inc.
Using a Conceptual Value of Information Approach to Decide When to, and When Not to, Replicate Systematic Reviews
Dr. Kednapa Thavorn, Ottawa Hospital Research Institute
Concurrent Session B7 — Oral Presentations
REAL-WORLD EVIDENCE
Incorporating Real-World Evidence Into Cancer Drug Funding Decisions In Canada: A Qualitative Study of Stakeholders’ Perspectives
Marc Clausen, St. Michael's Hospital, Li Ka Shing Knowledge Institute
Interhospital Transfer or Direct Transport to Specialized Centres for Thrombectomy: Interpretation of Quebec Results in Light of Late-Breaking, Real-World Evidence
Dr. Michèle de Guise, INESSS
Real-World Safety of Bevacizumab with First-Line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC): Population-Based Retrospective Cohort Studies in Three Provinces
Jaclyn Beca, Cancer Care Ontario
3:15 to 4:30 PMConcurrent Session C1 — Panel Discussion
The Pan-Canadian HTA Collaborative: A Year in Review
Ken Bond, Institute of Health Economics; Dr. Michèle de Guise, INESSS; Dr. Irfan Dhalla, Health Quality Ontario; Dr. Lesley Dunfield, CADTH; Kristen Moulton, CADTH; and Manik Saini, British Columbia Ministry of Health
C1 Webinar Recording
Concurrent Session C2 — Panel Discussion
Chasing Leprechauns: The Curious Future of Cancer Drug Reimbursement, Clinical Trials, HTA, and Real-World Evidence In Canada
Dr. Stuart Peacock, Canadian Centre for Applied Research in Cancer Control (ARCC); Dr. Winson Cheung, Cancer Control Alberta; Dr. Christopher McCabe, Institute of Health Economics; Dr. Kelvin Chan, Canadian Centre for Applied Research in Cancer Control (ARCC); and Carole McMahon, Patient
Concurrent Session C3 — Panel Discussion
Collaboration and Alignment Across Health Canada, CADTH, and INESSS
Dr. Trevor Richter, CADTH; Sylvie Bouchard, INESSS; Dr. Megan Bettle, Health Canada; and Dr. Amy Sood, CADTH
Concurrent Session C4 – Panel Discussion
Emerging Topics in the Implementation of E-Mental Health Services in Canada
Dr. Danielle Impey, Mental Health Commission of Canada; Allison Bichel , Alberta Health Services; and Elisabeth Smitko, Health Quality Ontario
Concurrent Session C5 – Panel Discussion
Knowledge Translation (KT) and Health Technology Reassessment (HTR): Unravelling the Black Box!
Rosmin Esmail, University of Calgary; Dr. Fiona Clement, University of Calgary; and Dr. Tom Stelfox, University of Calgary

Tuesday, April 16, 2O19

TimeActivityPresentations
7:30 to 8:45 AMBreakfast Session T1
Electronic Ordering Systems and Computerized Decision Support
Dr. Martin Reed, Children’s Hospital, Winnipeg
Breakfast Session T2
Building the Next Generation of Health Economists — Sowing the Seeds and Nurturing the Crop
Dr. Doug Coyle, University of Ottawa (moderator); Dr. Mike Paulden, University of Alberta; Dr. Jeff Round, Institute of Health Economics; and Karen Lee, CADTH
Breakfast Session T3
Addressing the Pressing Need for Modernizing and Expanding Training and Education in Health Technology Assessment in Canada
Dr. Adrian Levy, Dalhousie University
Breakfast Session T4
Harm Reduction: Making a Difference Through Policy Development and Implementation in Practice
Dianne Dyer, Alberta Health Services; and Amy Woroniuk, Alberta Health Services
Breakfast Session T5
Tackling the Thorny Issue of Patient Partner Compensation in Research and Health Care
Zal Press, Patient Commando
9:00 to 10:15 AMConcurrent Session D1 — Panel Discussion
Enhancing Access to the Oncology Biosimilars in Canada — Challenges and Opportunities
Dr. Chander Sehgal, Teva Canada Innovation; Sang Mi Lee, pan-Canadian Pharmaceutical Alliance; Jenn Gordon, Canadian Breast Cancer Network; Adam Haynes, CADTH; and Ross Wallace, Santis Health
Concurrent Session D2 — Panel Discussion
Incorporating Patient Input in CADTH and INESSS Drug Reviews: How is It Included and How Does It Inform CDEC, pERC, and CSEMI Deliberations?
Sarah Berglas, CADTH; Allen Lefebvre, Public Member, CDEC; Sylvie Bouchard, INESSS; Elizabeth Lye, Lymphoma Canada; Amanda Cresswell-Melville, Eczema Society of Canada; and Valerie McDonald, patient member, pERC
Concurrent Session D3 — Panel Discussion
The Costs and Benefits of Cannabis: Social, Medical, and Public Health Benefits
Dr. M-J Milloy, British Columbia Centre on Substance Use; Dr. Mark Ware, Chief Medical Officer, Canopy Growth Corporation; Dr. Brian Emerson, British Columbia Ministry of Health; and Dr. Judith Glennie, President, J.L. Glennie Consulting, Ltd.
Concurrent Session D4 — Panel Discussion
Supporting Health System Transformation: A Fireside Chat with the CADTH Executive Team
Dr. Brian O’Rourke, CADTH; Brent Fraser, CADTH; Lynda Jobin, CADTH; Dr. Michelle Mujoomdar, CADTH; and Dr. Harindra Wijeysundera, CADTH
Concurrent Session D5 — Panel Discussion
Emerging Issues in Health Economic Methods
Karen Lee, CADTH; Dr. Lauren E. Cipriano, Western University; Dr. Eldon Spackman, University of Calgary; Dr. Mike Paulden, University of Alberta; and Dr. Petros Pechlivanoglou, University of Toronto
D5 Webinar Recording
10:45 AM to 12:00 PMConcurrent Session E1 — Oral Presentations
HEALTH SERVICES FOR SENIORS
Functional Medication Management in Older Adults Living at Home: A Scoping Review
Hadeel Abed, University of Alberta
Reducing Inappropriate Medication Use Among Older Canadians Through Direct Patient Education and Engagement
Janet Currie, Canadian Deprescribing Network
Tablet-Based vs. Table-Top Cognitive Games for Older Adults: Which Are More Engaging?
Dr. Adriana Rios-Rincón, University of Alberta
The Use of Digital Storytelling in Older Adults with Dementia: A Systematic Literature Review
Dr. Lili Liu, University of Alberta
Concurrent Session E2 — Oral Presentations
MEDICAL DEVICES AND PROCEDURES
Incremental Cost-Effectiveness of Aspiration Therapy Versus Bariatric Surgery and No Treatment for Morbid Obesity
Dr. Hai Nguyen, Memorial University of Newfoundland
Introduction of New Health Technology in Surgery: Alberta Environment Scan (ES)
Dr. Paule Poulin, Alberta Health Services
An Innovative and Novel Approach to Assess a Non-Manual Room Disinfection Technology
Heather Gagnon, Alberta Health Services
HTA of New Technologies and Late-Breaking Trials: A Case Study of Transcatheter Mitral Valve Repair
Dr. Michèle de Guise, INESSS
Concurrent Session E3 — Oral Presentations
EQUITY, ETHICS, AND SOCIAL VALUES
Musings on Equity, Opportunity Cost, and Health Economic Evaluation
Tara Schuller, International Network of Agencies for Health Technology Assessment (INAHTA ) / Institute of Health Economics (IHE)
Picturing ELSI+ (Ethical, Legal, and Social Issues Plus Patient Values and Preferences) in Health Technology Assessment
Dr. Murray Krahn, Toronto Health Economics and Assessment (THETA) Collaborative
Social Values and Child Health Priorities: Empirical Evidence for Pediatric Drug Policy
Dr. Avram Denburg, The Hospital for Sick Children
Incorporating Ethics to Transform Health Technology Assessment in British Columbia
Katherine Duthie, British Columbia Ministry of Health
Concurrent Session E4 — Oral Presentations
OPIOIDS
Impact of Delisting High-Strength Opioid Formulations From a Public Drug Benefit Formulary on Opioid Utilization in Ontario
Diana Martins, Ontario Drug Policy Research Network
Opioids, Benzodiazepines, and Z-Drugs, Oh My! Introduction of a Personalized Prescribing Report to Alberta Physicians
Delaney Wiebe, College of Physicians and Surgeons of Alberta
How Expanding Community-Based Naloxone Dispensing Can Impact Health Services
Dr. Kay Rittenbach, Alberta Health Services; and Amy Woroniuk, Alberta Health Services
Psychosocial Interventions in the Treatment of Opioid Use Disorder: A Scoping Review
Prof. Cameron Wild, University of Alberta
E4 Webinar Recording
Concurrent Session E5 — Oral Presentations
KNOWLEDGE MOBILIZATION: EVIDENCE TO POLICY AND ACTION
Evidence Into Action: Using Knowledge Translation (KT) to Improve In-Patient Diabetes Management
Dr. Julie McKeen, University of Calgary
Integration of a Simple Framework for Translating Evidence into Policy at a Hospital-Based Health Technology Assessment Unit
Dr. Nisha Almeida, Health Technology Assessment Unit of the McGill University Health Centre
Development of a Policy Toolkit to Inform Canadian Policy-Makers Regarding Deprescribing
Dr. Cheryl Sadowski, University of Alberta
Concurrent Session E6 — Oral Presentations
CLINICIAN ENGAGEMENT
Health Economics In Clinical Practice Guidelines: The Know-Do Gap
Carmen Moga, Institute of Health Economics
The Opioid Wisely and Using Antibiotics Wisely Campaigns — A National Collaboration Between Choosing Wisely Canada and The College of Family Physicians of Canada
Dr. Allan Grill, The College of Family Physicians of Canada
Informational Discontinuity of Care and Culprit Drugs
Johanna Trimble, Patient Voices Network
Toronto Aortic Stenosis Quality of Life Scale (TASQ): Development of a Scale Based on a Canadian Aortic Stenosis Population and TAVI Patients
Dr. Rima Styra, University Health Network
Concurrent Session E7 — Oral Presentations
ONCOLOGY
Drug Access: How the Challenges Differ from Patients in Early Stage Breast Cancer Patients to People Living with Metastatic Breast Cancer
Diana Ermel, Canadian Breast Cancer Network
Development of a pan-Canadian Oncology Biosimilars Action Plan
Sang Mi Lee, pCPA
Initiatives to Improve the Timeliness of Cancer Diagnosis: Results From an Environmental Scan
Dr. Michelle Pollock, Institute of Health Economics
The Impact of Rarity on Oncology HTA and Funding in Ontario: A Review of pCODR Recommendations from 2012 to 2017
James Keech, Cancer Care Ontario
1:00 to 2:15 PMConcurrent Session F1 — Panel Discussion
Building the RWE Blueprint: A Coordinated Approach to RWE Use in Pharmaceutical Regulatory and Reimbursement Decisions in Canada
Tarry Ahuja, CADTH; Gayatri Jayaraman, Health Canada; Sylvie Bouchard, INESSS; and Dr. Kelvin Chan, Canadian Centre for Applied Research in Cancer Control (ARCC)
Concurrent Session F2 — Panel Discussion
Development of a Provincial Program for Fecal Microbiota Transplant for Clostridium Difficile Infections
Dr. Thach Lang, Alberta Health Services; Dr. Dina Kao, University of Alberta; Dr. Thomas Louie, University of Calgary; and Justin Riemer, Alberta Health Services (moderator)
Concurrent Session F3 — Panel Discussion
Clinical Decision Support Systems: Implications for Advancing Optimal Medical Imaging Use in Canada
Christa Bergquist, CADTH; Dr. Harindra Wijeysundera, CADTH; Dr. Martin Reed, Children’s Hospital, Winnipeg; Dr. Brian Rowe, University of Alberta; Mark McMillan, Alberta Health Services; and Lynne Zucker, Canada Health Infoway
Concurrent Session F4 – Panel Discussion
Collaboration for Transformation: Patients as Partners, Driving Patient Safety Improvement
Christopher Thrall, Canadian Patient Safety Institute (moderator); Sandi Kossey, Canadian Patient Safety Institute; Maryanne D’Arpino, Canadian Patient Safety Institute; and Katharina Kovacs Burns, Patients for Patient Safety Canada
F4 Webinar Recording
2:45 to 4:00 PMClosing Plenary
The Transformation Challenge
Join an expert panel to explore the challenges and opportunities associated with health system transformation. Drawing on content presented at the Symposium, on-site surveys of Symposium attendees, the broader HTA and health care communities, and other relevant sources, this plenary will provide an opportunity for informed dialogue and debate on hot topics and key issues in a novel and engaging format.
Heather Logan, Senior Advisor, Pharmaceutical Reviews, CADTH; Dr. Christopher McCabe, Executive Director and CEO, Institute of Health Economics; Mitch Moneo, Assistant Deputy Minister, Pharmaceutical Services Division, BC Ministry of Health; Dr. Brian O’Rourke, President and CEO, CADTH; Maureen Smith, Ontario Committee to Evaluate Drugs, OHTAC; and Helen Trifonopoulos, Head, Health Policy and Patient Access, Novartis Oncology
4:00 to 4:30 PMOfficial Closing
Dr. Brian O’Rourke, President and CEO, CADTH